We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-1.41%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.59B
AUM Growth
-$205M
Cap. Flow
-$105M
Cap. Flow %
-4.06%
Top 10 Hldgs %
43.13%
Holding
169
New
17
Increased
28
Reduced
45
Closed
8

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$42.8M
2
ABBV icon
AbbVie
ABBV
+$22.8M
3
BMY icon
Bristol-Myers Squibb
BMY
+$21.8M
4
CELG
Celgene Corp
CELG
+$14.3M
5
NVO
Novo Nordisk
NVO
+$10.1M

Top Sells

Rank Stock Value
1
ABT icon
Abbott
ABT
+$25.1M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$24.3M
3
AGN
Allergan plc
AGN
+$23.5M
4
GILD icon
Gilead Sciences
GILD
+$21.3M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$16.2M

Sector Composition

Rank Sector Weight
1 Healthcare 92.75%
2 Real Estate 2.87%
3 Financials 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXEL icon
51
Exelixis
EXEL
$14.1B
$11.8M 0.46%
388,822
– –
SAGE
52
DELISTED
Sage Therapeutics
SAGE
$11.2M 0.43%
+67,815
New +$6.57M
ELV icon
53
Elevance Health
ELV
$81.6B
$10.1M 0.39%
44,918
– –
ZBH icon
54
Zimmer Biomet
ZBH
$18.4B
$9.69M 0.37%
82,709
+12,875
+18% +$1.46M
CRL icon
55
Charles River Laboratories
CRL
$11.3B
$9.39M 0.36%
85,804
-41,296
-32% -$4.49M
MRUS
56
DELISTED
Merus
MRUS
$9.28M 0.36%
479,150
– –
LTC
57
LTC Properties
LTC
$2.06B
$9.13M 0.35%
209,673
+73,461
+54% +$3.4M
CLLS
58
Cellectis
CLLS
$287M
$9.04M 0.35%
310,250
– –
ACHC icon
59
Acadia Healthcare
ACHC
$2.62B
$8.89M 0.34%
272,400
– –
FOLD
60
DELISTED
Amicus Therapeutics
FOLD
$8.71M 0.34%
604,920
+329,426
+120% +$4.53M
AET
61
DELISTED
Aetna Inc
AET
$8.58M 0.33%
+47,566
New +$8.17M
BLUE
62
DELISTED
bluebird bio
BLUE
$8.39M 0.32%
3,636
+2,611
+255% +$5.3M
ALKS icon
63
Alkermes
ALKS
$8.39B
$7.88M 0.3%
+144,072
New +$7.35M
AVXS
64
DELISTED
AveXis, Inc. Common Stock
AVXS
$7.79M 0.3%
70,347
+60,347
+603% +$6.06M
SNY icon
65
Sanofi
SNY
$103B
$7.74M 0.3%
179,900
– –
DERM
66
DELISTED
Dermira, Inc.
DERM
$7.47M 0.29%
268,500
-128,400
-32% -$3.4M
ACAD icon
67
Acadia Pharmaceuticals
ACAD
$4.55B
$7.4M 0.29%
+245,885
New +$7.86M
EW icon
68
Edwards Lifesciences
EW
$50B
$7.34M 0.28%
195,300
-96,900
-33% -$3.56M
ENDP
69
DELISTED
Endo International plc
ENDP
$7.09M 0.27%
914,548
– –
RARE icon
70
Ultragenyx Pharmaceutical
RARE
$2.56B
$6.89M 0.27%
148,558
– –
NUVA
71
DELISTED
NuVasive, Inc.
NUVA
$6.87M 0.26%
117,437
-44,139
-27% -$2.5M
SNR
72
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
$6.68M 0.26%
883,919
+315,922
+56% +$2.64M
BSX icon
73
Boston Scientific
BSX
$68.4B
$6.56M 0.25%
+264,600
New +$7.3M
QURE icon
74
uniQure
QURE
$2.93B
$6.52M 0.25%
332,850
+91,829
+38% +$1.4M
IONS icon
75
Ionis Pharmaceuticals
IONS
$8.81B
$6.49M 0.25%
+128,930
New +$7.07M
1 2
3
4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2017 Portfolio in Review

As of Q4 2017, Tekla Capital Management held 169 positions worth $2.59B, down 7.3% from $2.8B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Tekla Capital Management withdrew a net $105M in Q4 2017, closing 8 positions and reducing 45 holdings. Its most notable exit was Intercept Pharmaceuticals, Inc., an estimated $7.15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Real Estate and Financials.

Against the trend, Tekla Capital Management opened a new position in Bristol-Myers Squibb worth $21.4M.

  • Tekla Capital Management's largest Q4 2017 buy was Bristol-Myers Squibb: 349,121 shares worth $21.4M.
  • Tekla Capital Management added most to Amgen in Q4 2017, an estimated $42.8M increase.
  • Tekla Capital Management's biggest Q4 2017 reduction was Abbott, cutting an estimated $25.1M.
  • Tekla Capital Management fully exited Intercept Pharmaceuticals, Inc. in Q4 2017, selling an estimated $7.15M.
  • Tekla Capital Management's ten largest holdings make up 43% of its $2.59B portfolio in Q4 2017.
  • Tekla Capital Management opened 17 new positions and closed 8 in Q4 2017.
  • Tekla Capital Management's portfolio value fell 7.3% quarter-over-quarter to $2.59B.

Based on Tekla Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.